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This study evaluates the effect oforal pancreaticenzyme supplements on pain, analgesic requirement
and the incidence ofcomplications in patients with acute pancreatitis. This double blind, prospectively
randomised placebo controlled study included 23 patients. Painwas monitored using a visual analogue
scale; the analgesic requirement was assessed with a numerical score.
No significant differences were noted between the median (range) pain scores ofpatients who
received placebo: 22 (17.1-58) and those who received enzymes: 23 (11.3 -63). Hospital stay was 7
(5-10) days in patients on placebo and 8 (6-24) days in the enzyme group (p 0.069). Analgesic
requirements were: placebo 20 (6-60) and enzymes: 16 (0-63) (p 0.56). This study has shown no
beneficial effect of oral pancreatic enzyme supplements in the initial management ofpatients with
acute pancreatitis.
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Feedback inhibition ofpancreatic secretions by intra-
duodenal proteases has been demonstrated in a number of
species-5. Enzyme supplementation has been suggested as
a means of pain relief in chronic pancreatitis but
application ofthis approach in acute pancreatitis has not
been reported previously. We postulate that intra-
duodenal proteases might reduce the secretory drive to
the pancreas and so might reduce the severity of the
pancreatitis; in animal models proglumide, a CCK
receptor antagonist, has been shown to have a beneficial
therapeutic effect when given after significant pancreatitis
had already been initiated6. The aim of the present study
was to evaluate the effect of pancreatic enzyme supple-
ments on pain and the incidence of complications in
patients with acute pancreatitis.
MATERIALSANDMETHODS
This study was approved by the Ethics Committee of
Southampton General Hospital.
*Addressfor correspondence."CDJohnson Southampton, General
Hospital, Southampton.
Patients
Twenty three patients, (13 men) median (range) age 67
(29-86) years were entered in the study (Table 1). All
patients had biochemically and radiologically proven
acute pancreatitis as defined by a serum amylase level >
1000 IU/L and ultrasonographic or computerised tomo-
graphy (CT) evidence ofoedematous/inflamed pancreas
with or without a peripancreatic collection. Patients with
both mild and severe forms of acute pancreatitis were
included in this study.
Only those patients who were receiving pancreatic
enzyme supplements or those allergic to porcine pan-
creatin were excluded. None of the patients received
octreotide, antisecretory agents or any other study drug in
this period.
StudyDesign
We used a double blind, prospectively randomised,
placebo controlled design. All patients gave written
informed consent before entering the study. Treatments
were randomised by random number tables and supplied
in identical containers, coded numerically.
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Table Demographic data, aetiological factors, predicted
severity of disease and complications
Placebo Pancreatic enzymes
Sex 9 male, 5 female 4 male, 5 female
Age 68.5 (29-85) 54 (36-86)
Aetiology alcohol (6) alcohol (6)
gallstones (5) gallstones (1)
Unknown (2) Unknown (3)
hyperparathyroidism (2)
steroid (1)
Predicted 12 mild 7 mild
Severity 2 severe 2 severe
Active capsules contained pancreatic enzymes as
enteric coated granules packaged in gelatine capsules
(Creon, Duphar Laboratories, UK). Each capsule con-
tained 210 units free protease, 440 units zymogen bound
protease, 8000 BP units lipase and 9000 BP units amylase.
Placebo capsules contained microcrystalline cellulose and
were identical in shape, size, appearance and taste to the
active enzyme capsules. Dosage was 3 capsules 4 times a
day, providing 7800 units of protease per day. Capsules
were given orally; if the patient could not swallow, the
capsules were opened and the granules were suspended in
a small volume ofwater and given through a nasogastric
tube. All patients had enzymes for aminimum offive days
but those predicted to have a severe attack based on the
modified Glasgow criteria or those who developed
complications received enzymes for a period of 10 days.
Those patients who were discharged before completing
the course of medication were given their remaining
medication to take home.
Pain suffered by the patientwas monitored daily using a
visual analogue scale. Each patient was asked to make a
mark on a 10 cm line to indicate the maximum pain he or
she had suffered over the previous 24 hours. The total pain
score was calculated by adding the pain scores marked by
the patient on each day of their hospital stay. Intra-
muscular opiate analgesia was prescribed in doses related
to body weight.
Other agents were prescribed according to the clinical
condition ofthe patient. The analgesic requirements were
calculated by assigning an arbitrary numerical score to
the analgesics used [injected opiates 3 points; diclofenac
and coproxamol (dextropropoxyphene and paracetamol)
2 points].
Length ofhospital stay and the incidence ofcomplica-
tions were also recorded. CT was performed one week
after admission, and at other times as clinically indicated in
all patients with complications and in those patients with
predicted severe disease based on the modified Glasgow
cirteria.
Statistical Analysis
Power calculation suggested that this studywould require
36 patients in each group assuming a 20% response in
either hospital stay, pain scores or analgesic requirements
with placebo and 50% with active medication in order to
achieve a 5% significance with 80% power.
Data were analysed using the Mann WhitneyU test.
RESULTS
Total pain scores were not significantly different between
the 2 groups,p 0.72 (Table 2). No significant difference
was found between the analgesic requirement scores in
patients on placebo and patients on pancreatic enzymes (p
0.56). Median hospital staywas not significantly different
between patients on placebo and patients receiving
enzymes, (p 0.069). Surgery was required in 9 patients in
the enzyme group and 7 in the placebo group. Five
patients underwent cholecystectomy; pancreatic debride-
ment was performed in 2 patients, one ofwhom also had
resection ofan infarcted left colon; the other patient was
re-explored for drainage ofa peripancreatic abscess. One
patient required laparotomy to establish the diagnosis of
pancreatitis and patient had a cystogastrostomy followed
by 2 re-explorations and packing for postoperative
bleeding.
Two patients required management in the intensive
care unit and one patient died. Complications arose in 5
ofthe 23 patients entered into the study with no difference
in incidence in the 2 groups. Two patients on pancreatic
enzymes developed pleural effusions with of them
having an associated chest infection. Three patients treat-
ed with placebo developed complications; patient had an
infected peripancreatic collection, patient developed
hypocalcemia while a third had an infarcted colon.
Significant nausea was reported by 11 ofthe 23 patients.
This led to early breaking of the randomisation code.
Nausea was reported by 7 patients who received placebo
and 4 patients given enzymes. Other side effects seen in
patient each were diarrhoea, excessive perspiration and
headache. Two patients developed symptoms and signs of
alcohol withdrawal.
Table 2 Summary of results of the analgesic scores, pain scores
and the length of hospital stay
Placebo Pancreatic enzyme
Median (range) Median (range)
Analgesic score 20 (6-60) 16 (0-63) p 0.56*
Total pain scores 22(17-58) 23 (11-63) p 0.72"
(mm)
Hospital stay (days) 7(5-10) 8(6-24) p 0.69"
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Four patients failed to complete the study; one patient
withdrew on the third day due to severe nausea and
perspiration, 2 patients were withdrawn on the first and
fourth day due to deterioration in their clinical condition
and patient withdrew on the third day due to symptoms
ofalcohol withdrawal.
Recalculation ofthepower estimates on the basis ofthe
observed analgesic requirements showed that more than
150 patients would be required in both treatment groups
to confirm the observed small difference in the analgesic
score. Because of this and the absence of any detectable
difference between the groups in complication rates,
hospital stay or total pain scores that might merit evalua-
tion in a larger series, a decision was made to terminate
the study.
DISCUSSION
In this prospectively randomised, placebo controlled
double blind study, we could find no evidence of any
beneficial effect ofpancreatic enzyme supplements in the
management ofthe initial stages ofacute pancreatitis. No
significant differences were seen in the pain scores, anal-
gesic requirements, the length of hospital stay and the
incidence of complications between the two groups
(Table 2).
Trypsin dependent feedback inhibition of pancreatic
secretion has been clearly demonstrated in rats 1,2,3. These
effects seem to be located in the upper intestine and
mediated by cholecystokinin3,8,9. The presence of
feedback inhibition of pancreatic enzymes by intra-
duodenal trypsin inman remains controversial. In a single
subject with an ampullary tumourl, Ihse et al. showed a
decrease in enzyme output and flow from the pancreas in
response to an intra-duodenal infusion oftrypsin orwhen
the patient’sown bile and pancreaticjuice was returned to
the intestine. This effect was abolished when a trypsin
inhibitor was added to the infusion fluid. Owyang ll
showed a dose related suppression of pancreatic output
and cholecystokinin levels by an intra-duodenal infusion
oftrypsin.
In a model ofacute haemorrhagic pancreatitis induced
by feeding mice a choline deficient diet, Niederau 13
showed that proglumide (CCK antagonist) had a
beneficial effect on survival and histology not only when
given early in the course of acute pancreatitis but also
when given after significant pancreatitis had already been
initiated. This effect was reversed when intravenousCCK
8 was given in conjuction with the proglumide.
Studies in 20 patients with chronic pancreatitis 13
demonstrated suppression of pancreatic enzyme
secretion by intra-duodenal infusion of proteases and a
significant decrease in pain was seen in patients with
chronic pancreatitis with associated exocrine insufficiency
when treated with pancreatic enzymes5,13,14,15. On the
other hand, studies by Hotz and Dlugosz 16,17 have failed
to show an increase in exocrine pancreatic secretion
following inhibition ofintra-duodenal trypsin. Krawiscz 18
failed to demonstrate feedback inhibition of pancreatic
secretion by the presence ofpancreato-biliary secretions
in the jejunum. More recently, Mossner19 showed that
treatment with exocrine pancreatic supplements in fact
increased pancreatic enzyme secretion andwas associated
with elevated cholecystokinin levels. The reasons for these
discrepancies include the difficulty ofcompletely diverting
pancreatic enzymes from the duodenum and of
completely inactivating luminal enzymes.
It is possible that control mechanisms in healthy
subjects and patients with pancreatic diseases may be
different and that the feedback inhibition oftrypsin may
be species specific.
The failure to demonstrate an effect on pancreatic
function by Hotz and Dlugosz 16, 17 could have been due
to the use of aprotinin as an inhibitor, which has only
a limited effect on chymotrypsin and also to the use
of a weak stimulus to pancreatic enzyme secretion.
Furthermore, studies showing feedback inhibition inman
have used pharmacological doses of trypsin5,1,ll,13. In
our study, we used approximately 7800 units ofprotease
per day, of which the total amount of trypsin and
chymotrypsin given was approximately 200-240mg each
per day, a dose commonly used in clinical practice for
enzyme replacement.
We were unable to demonstrate any beneficial effect on
the course of patients with acute pancreatitis with this
dose ofpancreatic enzymes.
Recent work in experimentally induced acute
pancreatitis2 has shown that acinar cell production of
trypsinogen decreases at an early stage in the course ofthe
disease. Thismay explain the failure ofnegative feedback
with pancreatic enzymes to modify the course of acute
pancreatitis in our study.
Phospholipase A2 which is implicated in the patho-
genesis of acute pancreatitis is not suppressed by the
protease, another possible explanation for the failure to
demonstrate the beneficial effect.
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